Last reviewed · How we verify

Coristina d

Brainfarma Industria Química e Farmacêutica S/A · Phase 3 active Small molecule

Coristina D is a combination antihistamine and decongestant that reduces allergy and cold symptoms by blocking histamine receptors and constricting nasal blood vessels.

Coristina D is a combination antihistamine and decongestant that reduces allergy and cold symptoms by blocking histamine receptors and constricting nasal blood vessels. Used for Symptomatic relief of allergic rhinitis, Symptomatic relief of common cold and upper respiratory congestion.

At a glance

Generic nameCoristina d
SponsorBrainfarma Industria Química e Farmacêutica S/A
Drug classAntihistamine/Decongestant combination
TargetH1 histamine receptor; alpha-1 adrenergic receptor
ModalitySmall molecule
Therapeutic areaAllergy/Cold and Flu
PhasePhase 3

Mechanism of action

The drug combines an antihistamine (likely chlorpheniramine or similar) to block H1 histamine receptors and reduce allergic symptoms such as itching and sneezing, with a decongestant (likely phenylephrine or pseudoephedrine) that acts as a sympathomimetic to constrict blood vessels in the nasal mucosa and reduce congestion. This dual mechanism provides symptomatic relief of both allergic and cold-related upper respiratory symptoms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: